Affinivax
Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases. This novel and highly efficient vaccine conjugation technology – named MAPS for Multiple Antigen Presenting System – has the potential to deliver novel vaccines that offer broader disease coverage than existing vaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today. The company is rapidly advancing a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform.
Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases. This novel and highly efficient vaccine conjugation technology – named MAPS for Multiple Antigen Presenting System – has the potential to deliver novel vaccines that offer broader disease coverage than existing vaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today. The company is rapidly advancing a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform.
Affinivax has raised $226M across 1 round. Its most recent round was a Series C of $226M in Jan 2021. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Affinivax is featured in
Similar companies
AI Metrics is an early stage company creating transformational image analysis technology that positions radiologists to be the most efficient, valuable clinicians in the patient care continuum
Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.
Bambusa Therapeutics is a biotechnology company that specializes in the development of bispecific antibodies.
Solarea Bio is a biotech company focused on developing microbial therapeutics to treat chronic inflammatory conditions and improve human health. They specialize in researching and creating natural-based therapeutics to address chronic inflammation, providing hospitals with effective medicinal options. By studying genomic sequences of microbes found in healthy foods, Solarea is able to create combinations of bacteria, fungi, and prebiotic fibers that have strong anti-inflammatory properties to target specific chronic illnesses. Their research has been tested in lab and animal studies, with their first application designed to help manage metabolic processes that lead to osteopenia and osteoporosis in postmenopausal women. Founded in 2017 in Cambridge, Massachusetts by Eric Schott, Gerardo Toledo, and Jillian DeWalt, Solarea Bio offers a natural solution to improve women's health and well-being.
Eclipse Bioinnovations is a leading RNA genomics company founded in 2017 based on technology developed at the University of California, San Diego. Eclipse's mission is to use their pioneering RNA genomics platform technologies to advance RNA medicines and scientific discovery. Eclipse’s founders developed eCLIP, the world’s most efficient and unique CLIP-seq technology for identifying RNA binding protein gene partners and gene maps. Eclipse’s suite of RNA genomics technologies now cover eCLIP-RBP for mapping the RNA binding proteins, miR-eCLIP for the miR-interactome, m6A-eCLIP for RNA modifications, End-Seq for 5' and 3' mapping, and FLI-Seq for simplifying Crispr library prep. Products are offered as services and kit for biopharma companies and academic researchers, and can be customized for clients.
Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease (PD) and extending across the brain and affected organs.
VST Bio is a biotechnology company that offers and develops treatment for vascular diseases.
Gate Bioscience is a biotech company that is developing a new type of medicine called Molecular Gates. These drugs are small molecules that selectively remove harmful extracellular proteins from inside the cell, where they originate. There are more than 4,000 extracellular proteins produced by humans, and over 1,000 of them can cause diseases when they function incorrectly. Molecular Gates aim to eliminate these disease-causing proteins, thereby eradicating the associated diseases for patients. The mechanism of action for Molecular Gates is unique, as they bind to a single channel in the cell through which extracellular proteins pass when they are secreted. By creating a "gate" in this channel, the Molecular Gates can block and recognize specific disease-causing proteins, preventing their exit from the cell. Consequently, the harmful proteins are degraded by the cell rather than being secreted. Gate Bioscience's mission to develop Molecular Gate medicines is supported by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. For more information, visit www.gatebio.com.
EpaleX is developing a novel inhaled treatment for epilepsy and migraine. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. When a seizure warning sign (aura) occurs, the patient will be able to prevent the development of a full-blown seizure through the use of a pocket nebulizer to deliver a powerful antiseizure medication that rapidly enters the brain and stops the seizure. The effect of the drug dissipates within minutes, allowing the patient to resume normal daily activity. The inhaler is also used to stop migraine attacks that are refractory to currently available migraine treatments.
iQure Pharma is a biotechnology company founded by entrepreneurs and ex-pharmaceutical executives that specializes in creating innovative treatments on a global scale.
Clever Carnivore is cell-cultured meat startup that uses stem cell biology, recombinant protein, and bioengineering to create cost-effective lab grown meats. With the company's high-efficiency model, cruelty-free, environmentally friendly, and cost-competitive technology it aims to produce sausage, burgers, and chicken nuggets.
The EVERY Company is the market leader in engineering, manufacturing and formulating animal-free, animal proteins as ingredients for the global food and beverage industry. Leveraging advanced fermentation to produce functional and nutritional proteins from microorganisms, the Company is reimagining the factory farm model that underpins industrial animal agriculture with a more sustainable, kinder, and healthier alternative. Clara Foods is on a mission to decouple the world's most powerful proteins from the animals that make them.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.